TRIACIN-C
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIACIN-C (TRIACIN-C).
TRIACIN-C is a combination of triamcinolone (a corticosteroid) and nystatin (an antifungal). Triamcinolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Nystatin binds to ergosterol in fungal cell membranes, causing pore formation and cell death.
| Metabolism | Triamcinolone is primarily metabolized in the liver via CYP3A4; nystatin is not absorbed systemically and is minimally metabolized. |
| Excretion | Renal: ~60% as unchanged drug; hepatic metabolism accounts for ~25% (primarily via CYP3A4), with biliary excretion of metabolites (~15%); fecal elimination <5%. |
| Half-life | Terminal elimination half-life: 7–9 hours. In patients with severe hepatic impairment (Child-Pugh C), half-life may extend to 15 hours; dosing adjustment recommended. |
| Protein binding | ~45% bound to albumin. Low affinity for alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 3.5–4.0 L/kg. Indicates extensive extravascular distribution; higher Vd observed in hypertensive patients. |
| Bioavailability | Oral: 25–40% (first-pass hepatic metabolism reduces bioavailability). Intranasal: limited systemic absorption (<10% but sufficient for decongestant effect). |
| Onset of Action | Oral: 30–60 minutes (therapeutic effect on nasal congestion). Intravenous: 5–15 minutes (blood pressure elevation). |
| Duration of Action | Oral: 4–6 hours (decongestant effect). Intravenous: 2–4 hours (pressor effect). Clinical note: tachyphylaxis may develop with prolonged use. |
5 mg orally twice daily, taken with meals to enhance absorption.
| Dosage form | SYRUP |
| Renal impairment | GFR 30-50 mL/min: 5 mg once daily. GFR 15-29 mL/min: 2.5 mg once daily. GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: 2.5 mg twice daily. Child-Pugh Class C: not recommended. |
| Pediatric use | Weight ≥20 kg: 0.1 mg/kg twice daily, maximum 5 mg per dose. Weight 10-19 kg: 0.05 mg/kg twice daily. Weight <10 kg: not established. |
| Geriatric use | Initiate at 2.5 mg twice daily; titrate based on renal function and tolerability; monitor for hypotension and electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIACIN-C (TRIACIN-C).
| Breastfeeding | Excretion in breast milk: Low concentrations. M/P ratio: 0.5 (estimated). Not expected to cause adverse effects in infant at maternal doses < 20 mg/day. However, high maternal doses may suppress infant adrenal function. Monitor infant for growth and adrenal suppression if maternal dose > 0.5 mg/kg/day. |
| Teratogenic Risk | Teratogenic risk: First trimester: Triamcinolone is a corticosteroid; animal studies show increased risk of cleft palate (approximately 3.5-fold). Human data limited; some studies suggest small increased risk of oral clefts. Second/third trimester: Prolonged use may cause fetal adrenal suppression, intrauterine growth restriction, and preterm delivery. Advise avoiding unless maternal benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component","Untreated bacterial or viral infections at application site","Fungal infections other than Candida"]
| Precautions | ["Systemic absorption of corticosteroids may cause reversible HPA axis suppression","Local irritation or sensitization may occur","Prolonged use may lead to overgrowth of non-susceptible organisms"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal: Blood pressure, blood glucose, signs of infection, adrenal suppression. Fetal: Ultrasound for growth restriction and amniotic fluid volume if prolonged use; neonatal assessment for adrenal insufficiency at birth. |
| Fertility Effects | Triamcinolone may impair fertility in animal studies. In humans, corticosteroids can suppress ovulation and menstrual regularity; no definitive long-term effect on fertility. |